#USA #New York #Levi & Korsinsky #Unicycive Therapeutics #NASDAQ UNCY

Unicycive Therapeutics Faces Class Action Lawsuit Amidst Controversy

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) finds itself in the spotlight as a class action lawsuit has been filed against the company. Investors who acquired shares between December 29, 2025, and June 29, 2026, are encouraged to participate. The lawsuit stems from allegations regarding misleading practices in the company’s communication with its shareholders concerning the New Drug Application (NDA) for oxylanthanum carbonate (OLC).

Background of the Allegations

According to the complaint, Unicycive spent approximately six months informing shareholders that its OLC application was proceeding smoothly. However, the core of the allegations is that the company did not conduct its own inspections to verify that the manufacturing vendor had resolved previously noted deficiencies by the FDA. This lack of independent oversight casts doubt on the accuracy of statements made by Unicycive about the readiness of its product for market launch.

On June 29, 2026, a critical deadline passed—the PDUFA target action date—wherein Unicycive’s shares were trading at a high of $8.56 just weeks prior. Yet, the next day, after the announcement of a second Complete Response Letter from the FDA, the stock plummeted by 39.1%, closing at $4.69. This substantial drop in stock price was attributed to investor reactions to what they perceived as a breach of trust by the company.

Key Timeline Events

The timeline surrounding this lawsuit is marked by several notable events:

• - December 29, 2025: Unicycive announces the resubmission of its FDA application for OLC, claiming the third-party manufacturer was making progress.
• - January 29, 2026: The FDA accepts the resubmission as a Class II complete response, with a target action date set for June 29, 2026.
• - March 30, 2026: In its FY2025 Form 10-K report, Unicycive indicated the resubmission was based on the manufacturer’s progress, without dwelling on the lack of their own inspections.
• - May 12, 2026: The company conveys that its FDA review remains “on track,” even as critical questions regarding third-party compliance were left unanswered.
• - June 30, 2026: Following the target action date, Unicycive announced another Complete Response Letter indicating ongoing manufacturing deficiencies. This revelation confirmed that the FDA had not conducted an inspection of the vendor, contrary to prior claims.

Implications and Investor Concerns

The claims in the lawsuit reflect essential concerns regarding transparency and investor trust in the pharmaceutical industry. The timing and nature of Unicycive’s disclosures have prompted inquiries into what assurances were actually verified before communication with shareholders occurred. Legal representative Joseph E. Levi highlighted the importance of timely disclosures, noting that “the accurate portrayal of material updates is fundamental for market integrity.”

Investors potentially affected by these developments are urged to reach out to Levi & Korsinsky, LLP for guidance on participation in the class action.

Moving Forward

As the legal proceedings unfold, shareholders who may have experienced losses during this turbulent period are encouraged to assess their eligibility to recover potential damages. Participation in a class action can often lead to a more streamlined process for those seeking redress.

The lawsuit was filed in the United States District Court for the Northern District of California, driven by the stipulations under the Private Securities Litigation Reform Act of 1995. For those who expressed concerns over receiving shared insights or are looking into joining the class action, they can prepare their documentation and speak directly to the legal team for a thorough examination of their case.

In these circumstances, the lessons drawn from Unicycive’s experience serve as a reminder of the critical nature of corporate accountability and the essential duty companies owe to their investors. As this case progresses, all eyes will be on the outcomes that could redefine investor relations in the biotech sector.